Project Grant R43EY030821

This federal Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $305,321.00 to Neovascularx, Inc. to clinically develop and commercialize topical ophthalmic products to treat neovascular age-related macular degeneration (NAMD). The long-term goal of this project is to create an accessible home-based topical treatment option for NAMD, which is the leading cause of vision loss among the elderly. The funding will support research and development of...

This Project Grant award from the National Eye Institute (NEI), part of the U.S. Department of Health and Human Services, supports the development of an antibody-based, gene-agnostic treatment for inherited retinal degeneration (IRD), with a focus on retinitis pigmentosa (RP). The $613,628 award to Piximune Inc. will fund research to create therapeutic antibodies that can eliminate debris from dead and dying photoreceptor cells, thereby reducing secondary damage and protecting surrounding...

The National Eye Institute (NEI), part of the Department of Health and Human Services, awarded a $600,032 Project Grant under the Vision Research federal grant program (CFDA 93.867) to Fannin Partners LLC, a Houston-based biomedical research company. The funding supports the development of SCG3 raptamers, a novel aptamer-based targeted therapy for wet age-related macular degeneration (wet AMD). Wet AMD is a prevalent eye disease affecting over 1.25M individuals in the U.S. Fannin Partners is...

This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides funding of $310,952 to Bedrock Therapeutics, Inc. to develop a novel gene therapy treatment for neovascular age-related macular degeneration (NAMD), a leading cause of blindness in people over 50. The goal is to create an innovative therapeutic approach using adeno-associated virus (AAV) vector technology to deliver single-chain immunomodulating proteins that can reduce inflammation and abnormal...

The National Eye Institute (NEI), under the U.S. Department of Health and Human Services, awarded a $693,423 Project Grant to the University of Mississippi Medical Center (UMMC) on September 15, 2025. The grant is funded through the NEI's Vision Research program (CFDA 93.867), which supports research aimed at understanding, preventing, and treating vision-related conditions and diseases. The project aims to develop a multivalent antibody cocktail to prevent and treat bacterial endophthalmitis, a...

The National Eye Institute (NEI) awarded a $312,239 Project Grant to Shift Pharmaceuticals Holdings, Inc. under the NEI's Vision Research federal grant program (CFDA 93.867) to develop antisense oligonucleotide (ASO) inhibitors targeting retinoic acid signaling. The goal is to mitigate vision loss in retinitis pigmentosa and age-related macular degeneration by reversing retinal remodeling, a key process that corrupts information processing in the visual system. Shift Pharmaceuticals, through its...

The National Eye Institute (NEI) awarded a $206,739 project grant titled "INSULIN-ACCELERATED SURGICAL APPROACH TO PRE-RETINAL GENE THERAPY" under its Vision Research program (CFDA 93.867) to The Ohio State University. The project aims to test a novel approach combining pre-retinal administration of adeno-associated virus (AAV) gene therapy with adjuvant insulin administration to accelerate AAV uptake into retinal cells. This research seeks to address limitations of current...

The National Eye Institute (NEI), under the U.S. Department of Health and Human Services, awarded a $730,000 Project Grant (CFDA 93.867 - Vision Research) to Human Cell Co, a for-profit biotech firm, to develop an optimized nerve growth factor (NGF) therapy for the treatment of dry eye disease (DED). The funding will support preclinical studies to evaluate the efficacy and mechanism of action of the company's proprietary NGF mutein (HC201) in improving tear film production and corneal...

This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $482,067 to Washington State University to develop novel nanotherapies for targeted treatment of corneal neovascularization (CONV), a sight-threatening condition characterized by the growth of blood vessels into the cornea. The project aims to synthesize a unique trehalose-based dendrimer (TRE-D) that can selectively target blood vessels in the cornea and deliver anti-angiogenic therapies when...

This $257,785 Project Grant was awarded on April 1, 2025 by the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867). The grant supports the development of a refillable micromachined lens capsule-based drug delivery device for extended intraocular delivery of biologics and immune-modulating peptides to treat non-infectious uveitis. The key products/services to be delivered under this 4-year grant include: Characterizing and controlling the release of the...